1.Qu Y, Chen C, Sun F, Liu S, Zhao G, Zhao Z, Liu C, Jiang X, Li T. Epigenetic modulation with nanosatellite triggers tumoricidal immunity for hepatocellular carcinoma treatment. Nat Commun 2025;16(1):7340.
2.Li RZ, Pan GQ, Xiong C, Ding ZN, Zhang TS, Yan LJ, Wang D, Zhang X, Dong XF, Yan YC, Zhou Y, Dong R, Dong ZR, Li T. Hypoxia-Induced Creatine Uptake Reprograms Metabolism to Antagonize PARP1-Mediated Cell Death and Facilitate Tumor Progression in Hepatocellular Carcinoma. Cancer Res. 2025 ;85(19):3671-3688.
3.Sun F, Yan Y, Sun D, Liu S, Dong Z, Pan G, Zhang L, Shao X, Xu Y, Qu Y, Li T. Targeting CAMK1D-engineered nanoactivator suppresses cancer stem cell maintenance and immune evasion in enzalutamide-resistant prostate cancer. Theranostics. 2026;16(6):2918-2935.
4.Pan GQ, Yan YC, Li RZ, Xiong C, Zhang SP, Qu Y, Dong R, Zhou Y, Zhang TS, Chen ZQ, Zhang XL, Dong XF, Wang DX, Dong ZR,Li T. Targeting SAMD1 enhances the effect of anti-PD-1 plus lenvatinib therapy in hepatocellular carcinoma by increasing ferroptosis sensitivity and immune response. Metabolism 2025:156304.
5.Dong ZR, Sun D, Yang YF, Zhou W, Wu R, Wang XW, Shi K, Yan YC, Yan LJ, Yao CY, Chen ZQ, Zhi XT,Li T. TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB-EGF Expression and Proteolytic Cleavage. Hepatology2020; 72:923-939
6.Guo X, Tan S, Wang T, Sun R, Li S, Tian P, Li M, Wang Y, Zhang Y, Yan Y, Dong Z, Yan L, Yue X, Wu Z, Li C, Yamagata K, Gao L, Ma C,Li T, Liang X. NAD+ salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity. Hepatology 2023，78(2): 468-485.
7.Wang DX, Long JY, Li RZ, Zhang DL, Liu H, Liu J, Tian JC, Li H, Liu J, Zhao HT, Li T. Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments. Mol Cancer. 2024;23(1):15.
8.Wang Q, Zhang X, Han C, Lv Z, Zheng Y, Liu X, Du Z, Liu T, Xue D,Li T, Wang L. Immunodynamic axis of fibroblast-driven neutrophil infiltration in acute pancreatitis: NF-κB-HIF-1α-CXCL1. Cell Mol Biol Lett. 2025 ;30(1):57
9.Yan YC, Shao LJ, Meng GX, Pan GQ, Li RZ, Xiong C, Liu SJ, Ding ZN, Zhang XL, Dong XF, Qu Y, Dong ZR, Li T. Targeting FAM111B attenuates mitophagy and increases the sensitivity to lenvatinib treatment by increasing MFN2 stability in hepatocellular carcinoma. Cell Death Dis. 2025;16(1):645.
10.Cao QH, Li H, Sun PF, Lu DH, Tian BW, Jiao KF, Tian JC, Wang YX, Jia JS, Zhang ZH, He Q, Peng SX, Zhang DL, Dong ZR, Wang DX, Li T. Pathomics-Integrated Multimodal Model Evaluate Chemoimmunotherapy Efficacy in Unresectable Intrahepatic Cholangiocarcinoma. JHEP Reports,22;7(11):101557
11.Zhang Z, Li H, Wang Y, Liu J, Guo M, Sun P, Lu D, Cao Q, Zhang D, He Q, Jia J, Dong Z, Liu C, Chen P, Zhao L, Wang D, Liu J, Li T. Integrated Radiotherapy with Immune-Chemotherapy for Unresectable Biliary Tract Cancer: An Exploratory Pilot Study. Int J Radiat Oncol Biol Phys. 2026:S0360-3016(26)00014-3.
12.Han Li, Peng-Fei Sun, Jun-Yu Long, Hong-Zhi Liu, Qi-Rui Zhang, Zhong-Chao Li, Yong-Yi Zeng, Xin-Yu Bi, Ya-Jin Chen, Zhong Chen, Zhi-Yong Huang, Ming Kuang, De-Yu Li, Xiang-Cheng Li, Xiao Liang, Fu-Bao Liu, Shi-Chun Lu, Tao Peng, Tian-Qiang Song, Hui-Chuan Sun, Kui Wang, Nan-Ya Wang, Tian-Fu Wen, Bao-Cai Xing, Li Xu, Tao Yin, Lei Zhang, Shui-Jun Zhang, Le-Du Zhou, Lei Zhao, Hai-Tao Zhao, Dong-Xu Wang, Tao Li; China Liver Cancer Study Group Young Investigators (CLEAP). Associated factors identification and predictive model development for perioperative risk in patients with hepatocellular carcinoma receiving preoperative immunotherapy. HBSN 2026.
13.Ying Qu, Jingjing Zhao, Long Ma, Xue Wang, Feifei Sun, Yizhe Li, Yihua Wu, Guozhi Zhao, Shijia Liu, Wenqing Ma, Tao Li, Zhongxi Zhao. Intranasal delivery of temozolomide and disulfiram in situ gel combined with copper for enhanced glioblastoma therapy. Colloids and Surfaces B: Biointerfaces, 2025: 255,114898
14.Dong ZR, Zhang MY, Qu LX, Zou J, Yang YH, Ma YL, Yang CC, Cao XL, Wang LY, Zhang XL,Li T. Spatial resolved transcriptomics reveals distinct cross-talk between cancer cells and tumor-associated macrophages in intrahepatic cholangiocarcinoma. Biomark Res. 2024 ;12(1):100.
15.Tan S, Zhang X, Guo X, Pan G, Yan L, Ding Z, Li R, Wang D, Yan Y, Dong Z, Li T. DAP3 promotes mitochondrial activity and tumour progression in hepatocellular carcinoma by regulating MT-ND5 expression. Cell Death Dis. 2024;15(7):540.
16.Mao XC, Shi S, Yan LJ, Wang HC, Ding ZN, Liu H, Pan GQ, Zhang X, Han CL, Tian BW, Wang DX, Tan SY, Dong ZR, Yan YC,Li T. A model based on adipose and muscle-related indicators evaluated by CT images for predicting microvascular invasion in HCC patients. Biomark Res 2023;11(1):87.
17.Yan YC, Meng GX, Yang CC, Yang YF, Tan SY, Yan LJ, Ding ZN, Ma YL, Dong ZR,Li T. Diacylglycerol lipase alpha promotes hepatocellular carcinoma progression and induces lenvatinib resistance by enhancing YAP activity. Cell Death Dis 2023;14(7):404.
18.Lun-Jie Yan, Long-Shan Yang, Yu-Chuan Yan, Si-Yu Tan, Zi-Niu Ding, Hui Liu, Dong-Xu Wang, Zhao-Ru Dong,Tao Li. Anthropometric Indicators of Adiposity and Risk of Primary Liver Cancer: A Systematic Review and Dose-Response Meta-analysis. European Journal of Cancer 2023；185:150-163
19.Dong ZR, Ke AW,Li T, Cai JB, Yang YF, Zhou W, Shi GM, Fan J. CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity. Mol Cancer2021;20(1):75.
20.Dong ZR, Cai JB, Shi GM, Yang YF, Huang XY, Zhang C, Dong RZ, Wei CY, Li T, Ke AW, Fan J. Oncogenic miR-93-5p/Gal-9 axis drives CD8 (+) T-cell inactivation and is a therapeutic target for hepatocellular carcinoma immunotherapy. Cancer Lett 2023;564:216186.
21.Yan LJ, Yao SY, Meng GX, Liu KX, Li HC, Ding ZN, Dong ZR, Hong JG, Chen ZQ,Li T. Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis. Hepatol Int 2021;15:1413-1420.
22.Su P, Hong J,Li T.An Uncommon Lesion of the Liver. Gastroenterology. 2021:7:2258-2260.（case report)
23.Dong ZR, Zhi XT,Li T. A rapidly progressing polycystic liver disease? Gastroenterology 2020;158(1):e9-e11.（case report)
24.Pan GQ, Yan YC, Li RZ, Dong ZR, Li T. Response to "expanding the clinical and Immunogenomic relevance of SAMD1 in hepatocellular carcinoma". Metabolism. 2025:156336.
25.Liu H, Li H, Wang DX, Li T. Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis. Hepatology 2024 1;79(5):E144-E145
